Literature DB >> 20437214

Impact of change in high-density lipoprotein cholesterol from baseline on risk for major cardiovascular events.

David L Laitinen1, Shivaji Manthena.   

Abstract

INTRODUCTION: Low concentration of high-density lipoprotein cholesterol (HDL-C) has increasingly been recognized as a strong and independent predictor of cardiovascular risk. The aim of this study was to determine the association between change in HDL-C concentration from baseline and risk of a major cardiovascular event in a commercially insured population cohort with suboptimal HDL-C and low-density lipoprotein cholesterol (LDL-C) concentrations at baseline.
METHODS: A retrospective longitudinal survival analysis was conducted using claims data from a large, commercial US health plan. To be included, patients had to be > or =50 years of age on the index date (laboratory test date between January 1, 2000 and December 31, 2003 on which both their LDL-C and HDL-C were not at goal), be continuously enrolled for a minimum of 6 months prior to and 12 months after the index date, and had to have at least one other laboratory panel result within 1 year prior to the cardiovascular event or study disenrollment. Cox proportional hazards analysis was conducted to assess the association between change in HDL-C concentrations and risk of a major cardiovascular event (defined as a > or =1-day hospitalization for a cardiovascular disease [CVD] diagnosis or an invasive cardiovascular procedure) within 5 years of the index date, after adjusting for covariates.
RESULTS: A 0.026 mmol/L (1 mg/dL) increase in HDL-C from baseline was associated with a statistically significant 1.9% decreased risk of a major cardiovascular event (P<0.0001; hazard ratio: 0.981; 95% CI: 0.974, 0.989), after adjustment for covariates.
CONCLUSION: Our finding of an inverse association between change in HDL-C concentrations and risk of a major cardiovascular event confirms previously reported results. Increasing HDL-C concentrations may serve as an effective measure for preventing future cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437214     DOI: 10.1007/s12325-010-0019-4

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  5 in total

1.  Association between the rs1805081 polymorphism of Niemann-Pick type C1 gene and cardiovascular disease in a sample of an Iranian population.

Authors:  Masoumeh Afzali; Mohammad Hashemi; Seyed Payman Tabatabaei; Kourosh Tirgar Fakheri; Alireza Nakhaee
Journal:  Biomed Rep       Date:  2016-11-07

2.  Serum Lipids and Cardiovascular Disease Mortality in Iranian Population: Joint Modeling of Longitudinal and Survival Data in Tehran Lipid and Glucose Study (TLGS) Cohort.

Authors:  Bagher Pahlavanzade; Farid Zayeri; Taban Baghfalaki; Farzad Hadaeg; Davood Khalili; Mohammad Shoaib Hamrah; Edwin Paul; Fereidoun Azizi; Alireza Abadi
Journal:  Galen Med J       Date:  2019-09-18

3.  Aberrant promoter methylation profile of Niemann-pick type C1 gene in cardiovascular disease.

Authors:  Masoumeh Afzali; Alireza Nakhaee; Seyed Payman Tabatabaei; Kourosh Tirgar-Fakheri; Mohammad Hashemi
Journal:  Iran Biomed J       Date:  2013-04

4.  Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium.

Authors:  Martin Bahls; Matthias W Lorenz; Marcus Dörr; Lu Gao; Kazuo Kitagawa; Tomi-Pekka Tuomainen; Stefan Agewall; Gerald Berenson; Alberico L Catapano; Giuseppe D Norata; Michiel L Bots; Wiek van Gilst; Folkert W Asselbergs; Frank P Brouwers; Heiko Uthoff; Dirk Sander; Holger Poppert; Michael Hecht Olsen; Jean Philippe Empana; Ulf Schminke; Damiano Baldassarre; Fabrizio Veglia; Oscar H Franco; Maryam Kavousi; Eric de Groot; Ellisiv B Mathiesen; Liliana Grigore; Joseph F Polak; Tatjana Rundek; Coen DA Stehouwer; Michael R Skilton; Apostolos I Hatzitolios; Christos Savopoulos; George Ntaios; Matthieu Plichart; Stela McLachlan; Lars Lind; Peter Willeit; Helmuth Steinmetz; Moise Desvarieux; M Arfan Ikram; Stein Harald Johnsen; Caroline Schmidt; Johann Willeit; Pierre Ducimetiere; Jackie F Price; Göran Bergström; Jussi Kauhanen; Stefan Kiechl; Matthias Sitzer; Horst Bickel; Ralph L Sacco; Albert Hofman; Henry Völzke; Simon G Thompson
Journal:  Eur J Prev Cardiol       Date:  2019-10-16       Impact factor: 7.804

5.  Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments.

Authors:  Sebastian Schneeweiss; Jeremy A Rassen; Robert J Glynn; Jessica Myers; Gregory W Daniel; Joseph Singer; Daniel H Solomon; Seoyoung Kim; Kenneth J Rothman; Jun Liu; Jerry Avorn
Journal:  BMC Med Res Methodol       Date:  2012-11-26       Impact factor: 4.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.